Literature DB >> 23435443

Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.

P Ravn1, A G Haugen, D Glintborg.   

Abstract

AIM: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in premenopausal women affecting 5-10%. Nearly 50% are overweight or obese, which result in a more severe phenotype of PCOS. Weight loss is therefore considered the first line treatment in overweight women with PCOS. The aim of this study was to appoint evidence based and clinically applicable advises on weight loss in overweight women with PCOS.
METHODS: A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS. The primary outcome was weight loss. The clinical manifestations of hyperandrogenism and menstrual cyclicity were secondary outcomes. Metabolic parameters were not included in the present review.
RESULTS: Weight loss is most effectively achieved through a 12-1500 kcal/day diet, which results in a clinically relevant weight loss. The type of diet has no implications for degree of weight loss. Physical activity has no significant additive effect on weight loss. Metformin combined with a low calorie diet has subtle additive effect on weight loss and level of androgens when compared to diet alone.
CONCLUSION: Weight loss through life style changes, preferably a low calorie diet, should be the first line treatment in overweight/obese women with PCOS. Metformin can be considered as an additional treatment but has subtle additive effect.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435443

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  7 in total

1.  Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial.

Authors:  Ashraf Moini; Mahia Kanani; Ladan Kashani; Reihaneh Hosseini; Ladan Hosseini
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

2.  Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.

Authors:  Dorte Glintborg; Hanne Mumm; Magda Lambaa Altinok; Bjørn Richelsen; Jens Meldgaard Bruun; Marianne Andersen
Journal:  J Endocrinol Invest       Date:  2014-06-07       Impact factor: 4.256

Review 3.  Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.

Authors:  L I Igel; A Sinha; K H Saunders; C M Apovian; D Vojta; L J Aronne
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

4.  Metformin Protects Cells from Mutant Huntingtin Toxicity Through Activation of AMPK and Modulation of Mitochondrial Dynamics.

Authors:  Jing Jin; Hao Gu; Nicole M Anders; Tianhua Ren; Mali Jiang; Michael Tao; Qi Peng; Michelle A Rudek; Wenzhen Duan
Journal:  Neuromolecular Med       Date:  2016-05-25       Impact factor: 3.843

5.  Weight change therapy as a potential treatment for end-stage ovarian carcinoma.

Authors:  Kuat Pernekulovich Oshakbayev; Kenneth Alibek; Igor Olegovich Ponomarev; Nurlybek Nurlanovich Uderbayev; Bibazhar Abayevna Dukenbayeva
Journal:  Am J Case Rep       Date:  2014-05-12

6.  Assessment of C-reactive Protein and C3 as Inflammatory Markers of Insulin Resistance in Women with Polycystic Ovary Syndrome: A Case-Control Study.

Authors:  Setareh Dehdashtihaghighat; Abolfazl Mehdizadehkashi; Amirmohsen Arbabi; Mohadeseh Pishgahroudsari; Shahla Chaichian
Journal:  J Reprod Infertil       Date:  2013-10

7.  Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.

Authors:  Saghar Salehpour; Sedighe Hosseini; Leila Nazari; Nasrin Saharkhiz; Shahrzad Zademodarres
Journal:  JBRA Assist Reprod       Date:  2018-09-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.